Abstract
Background:
Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous group of hepatic disorders that can progress rapidly, leading to cirrhosis and death due to liver failure. Mutations and variations in three genes, including ATP8B1, ABCB11, and ABCB4, have been reported to be the main genetic cause of three subtypes of this disorder including PFIC1, PFIC2, and PFIC3, respectively.Objectives:
Therefore, the aim of this study was to investigate more common mutations and variations associated with PFIC considering clinical and Para-clinical features of the disease.Methods:
Thirty-five unrelated patients with PFIC from the south of Iran were selected randomly among all PFIC patients referring to Namazi hospital, affiliated to Shiraz University of Medical Sciences. Genomic DNA was extracted from the peripheral blood lymphocytes. Sequences related to these variations were then amplified by PCR in the 35 cholestasis patients and analyzed by Sanger® sequencing.Results:
The results showed that there was no variation in interest exon of ABCB4. Moreover, in ATP8B1, there was no prevalent mutation and only an unknown significant variation (c.*1101 + 366G > A) was found. However, in the ABCB11 gene, different variations were found including c.1434 + 174G > A, c.1434 + 70C > T, c.1331T > C (p.Val444Ala, a common variant proposed to be associated with cholestasis), c.1309-93G > A, c.1309-165C > T. Also, 11 and 13 cases showed heterozygote and homozygote, respectively, for V444A variation of the ABCB11 gene.Conclusions:
The allele frequency of V444A in this study was 52.8%. This variation has been previously implicated with higher frequencies in ICP and DIC than normal subjects, suggesting that this variation may become disease-relevant in certain conditions.Keywords
1. Background
Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous class of autosomal recessive hepatic disorders that begins in the neonatal period or first year of life and usually progresses to cirrhosis within the first decade of life (1, 2). PFIC can progress rapidly and result in cirrhosis during infancy, leading to death due to liver failure at ages usually between infancy and adolescence (1, 2).
Until now, genetic and molecular studies have identified three subtypes of PFIC, which include PFIC1 (the former Byler disease), PFIC2, and PFIC3 as a result of mutations in genes involved in bile formation. PFIC1 is due to ATP8B1 gene mutations, which can cause the milder phenotype (3). PFIC2 is caused by mutations in the ABCB11 gene (4, 5). This gene which is located on human chromosome 2q24 encodes the ATP-dependent canalicular bile salt export pump (BSEP) in liver and the loss of BSEP function responsible for the decreased biliary bile salt secretion resulting in the accumulation of bile salts inside the hepatocyte and finally severe hepatocellular cholestasis (6). PFIC3 results from diseases causing variants in the ABCB4 gene located on chromosome 7q21. This gene is translated into the protein MDR3 with an essential role in biliary phospholipid (phosphatidylcholine) excretion across the canalicular membrane (7-9). Bile from patients with PFIC3 is not inactivated by phospholipids (with very low concentrations of phospholipid) that results in bile canaliculi and biliary epithelium injuries, leading to cholangitis and cholestasis cholestatic liver disease (10). Given the fact that different ATP8B1, ABCB11, and ABCB4 variants have been associated with cholestasis, we made an attempt to investigate the most common variants reported in these genes among 35 patients with cholestasis.
2. Methods
2.1. Patients
Thirty-five unrelated patients with cholestasis from the south of Iran were enrolled in this study. All cholestasis patients were diagnosed by a group of gastroenterohepatology specialists in gastroenterohepatology ward of Namazi hospital, affiliated to Shiraz University of Medical Sciences, on the basis of characteristic symptoms such as jaundice, dark urine, light-colored stools, and generalized itchiness. The patients were selected randomly. All the patients gave informed consent before undergoing genetic analysis for common variations of ATP8B1, ABCB4, and ABCB11. Three-milliliter whole-blood samples were collected from the patients, drawn into EDTA tubes, and stored at -20ºC until use.
2.2. Preparation of Genomic DNA
Genomic DNA was extracted from the peripheral blood lymphocytes by QIAamp DNA Blood Mini Kit (QIAGEN, Germany) according to the manufacturer’s instructions. The genomic DNA concentration was measured by NanoDrop (ND1000, USA) and stored at - 20ºC until use.
2.3. PCR and Sequencing
Sequences covering the variations of ATP8B1 (I661T, exon 18), ABCB4 (p.R652G, exon 16), and ABCB11 (p.V444A, exon 13) in 35 cholestasis patients were amplified by PCR primers given in Table 1. These primer pairs were designed and evaluated on the basis of the ATP8B1, ABCB4, and ABCB11 reference genomic sequences (ENSEMBLE) using NCBI-BLAST, UCSC (BLAT and In Silico PCR) and Allele ID 7.5 (Table 1). The total volume of the PCR was 50 μL containing 1 μL of each primer (20 pmol/μL), 1 μL DNA template (50 - 200 ng), 25 μL TEMPase Hot Start 2x Master Mix Blue (Ampicon, A290806), and 22 μL dH2O. The PCRs were carried out according to Amplicon TEMPase Hot Start protocol and programs given in Table 1. Ten microliters of the PCR products were visualized on 2% agarose gel containing SYBR Safe.
Primers and PCR Protocols Used for Amplification of the Interest Exons of ATP8B1 (NI661T), ABCB4 (R652G) and, ABCB11 (V444A) Genes
| Gene (Interest Variant) | Primer Sequence | PCR Program | PCR Product |
|---|---|---|---|
| ATP8B1 (NI661T) | Forward: GGATGATAAAGCCAGACCTTGT | 95°C for 15 min, 35 cycles for: 95°C, 30 sec, 64°C, 30 sec, 72°C, 20 sec, and final extension 72°C, 7 min | 502 bp |
| Reverse: GTGCCAGTGTCAAATGCTGAA | |||
| ABCB4 (R652G) | Forward: TCCTTGATTGAGAAGCAGTTAG | 95°C, 15 min, 35 cycles for: 95°C for 30 sec, 59°C for 30 sec, 72°C for 30 sec, and final extension 72°C for 7 min | 571 bp |
| Reverse: GCATCTCAGCGTAAAGACTAC | |||
| ABCB11 (V444A) | Forward: TCTTGGTCATGGCTCTCA | Touch Down PCR, 95°C for 15 min, 20 cycles for: 95°C for 30 sec, 67°C for 30 sec (-0.5°C per cycle), 72°C for 20 sec, 15 cycles for:95°C 30 sec, 58°C 30 sec, 72°C for 25 sec, and final extension 72°C for 7 min | 626 bp |
| Reverse: ATCACTGACTGAAATGTTGC |
2.4. DNA Sequencing
PCR products of interest exons and exon-intron boundaries of three mentioned genes in our 35 patients were analyzed by DNA sequencing. Sanger sequencing data were analyzed using NCBI BLAST and Codon Code Aligner software.
3. Results
A total of 35 patients (70 alleles) with progressive intrahepatic cholestasis were studied for detection of common variants associated with this disorder in interest exons of ATP8B1 (I661T), ABCB4 (p.R652G), and ABCB11 (p.V444A). There was not identified any variation in interest exon of ABCB4. Also, in ATP8B1, a prevalent mutation was not identified, and only an unknown significant variation (c.*1101 + 366G > A) was identified in patients 4, 9, 15, 21, 26, and 29 as heterozygote and patient 14 as homozygote. However, in ABCB11 gene, different variations were found including c.1434 + 174G > A, c.1434 + 70C > T, c.1331T > C (p.Val444Ala, common variant), c.1309-93G > A, and c.1309-165C > T. Since among these variations, only p.Val444Ala is important due to its susceptibility and association with intrahepatic cholestasis, its distribution in our patients are given in Table 2.
Clinical and Para Clinical Sings of the Patients and Distribution of c.1331T > C (p.Val444Ala) in ABCB11 Gene among Our Patients
| Case No. | ABCB11 | ABCB4 | ATP8B1 | Clinical Signs | Para Clinical Findings | Treatment |
|---|---|---|---|---|---|---|
| 1. | 1 | ND | Jaundice, Itching, Bleeding Tendency, Fever, Tea Color Urine | Enlarged Liver, Normal Echo, Intracellular and Intracalcinular Cholestasis, Fibrosis | LT | |
| 2. | Hom. | ND | ND | pruritus, Ascites, GI bleeding, encephalopathy | increased liver echo, cholestasis, giant cell formation, cirrhosis | LT |
| 3. | ND | ND | ND | Pruritus, clay stool, itching, jaundice, hepatomegaly, irritability | heterogeneous echo of the liver, enlarged spleen, destruction of lobular and vascular architecture, nodule formation, cirrhosis | LT |
| 4. | Het. | ND | Het. | poor growth, pruritus, encephalopathy, ascites, GI bleeding, | enlarged liver, coarse echo, chronic hepatic parenchymal damage, focal steatosis and ballooning degeneration, fibrosis | LT |
| 5. | Hom. | ND | ND | Jaundice | increased echo, enlarged liver, enlarged spleen, cirrhosis | LT |
| 6. | Het. | ND | ND | pruritus, vomiting, diarrhea, fatty stool, tea color urine hepatomegaly, itching | enlarged liver, enlarged spleen, fibrosis, cirrhosis | LT |
| 7. | Hom. | ND | ND | jaundice, icteric sclera, itching | liver coarse echo | LT |
| 8. | Het. | ND | ND | Jaundice, pruritus, encephalopathy | liver prominent size, enlarged spleen, cirrhosis, giant cell hepatitis | LT |
| 9. | Het. | ND | Het. | Jaundice | Elevated liver enzymes, heterogeneous echo, relative destruction of lobular and vascular architecture, fibrosis | LT |
| 10. | Hom. | ND | ND | Jaundice | Elevated liver enzymes, splenomegaly, hepatomegaly, hyperechoic lesion, spotty necrosis, infiltration of lymphocytes, fibrosis | LT |
| 11. | ND | ND | ND | Jaundice | enlarged liver, increased echo of hepatic biliary tree, infiltration of inflammatory cells, fibrosis | LT |
| 12. | Hom. | ND | ND | Jaundice, Yellowish Skin, encephalopathy, GI bleeding, Ascites, Pruritus | enlarged spleen, inhomogeneous echo, cirrhosis | LT |
| 13. | Hom. | ND | ND | Pruritus | mucosal thickening of Gall bladder, Ascites, fibrosis | LT |
| 14. | Hom. | ND | Hom. | Pruritus, Pruritus Yellow Skin, And Sclera, Itching Wound | Altered liver enzymes | LT |
| 15. | Hom. | ND | Hom. | Pruritus, Ascites Jaundice, Encephalopathy | irregular outline of liver, coarse echo, spleen prominent size ascites pleural effusion, Cirrhosis, chronic cholecystitis | LT |
| 16. | ND | ND | ND | No data was available | No data was available | - |
| 17. | Hom. | ND | ND | Jaundice | enlarged liver, inhomogeneous echo | LT |
| 18. | Het. | ND | ND | Itching, Jaundice, anorexia, pruritus encephalopathy, GI bleeding | enlarged liver, Gall stone, duct proliferation, inflammation, Rosette formation, Feathery changes | LT |
| 19. | ND | ND | ND | Itching, intractable pruritus | Altered liver enzymes | LT |
| 20. | ND | ND | ND | Itching, severe pruritus | Altered liver enzymes, increased liver echo | LT |
| 21. | Hom. | ND | Het. | Jaundice, icterus | liver prominent size, hyperechoic liver, spleen prominent size, Extensive Fibrosis, portal fibrosis, ductular proliferation, cholestasis | Liver biopsy |
| 22. | Hom. | ND | ND | Jaundice, icterus | Elevated liver enzymes, Liver coarse echo, enlarged spleen, destruction of lobular and vascular architecture, nodule formation, fibrosis | LT |
| 23. | Hom. | ND | ND | Jaundice, pruritus, encephalopathy, ascites, GI bleeding, palmar erythema, GI bleeding | patent spleen, giant cell formation, feathery degeneration, fibrosis | LT |
| 24. | ND | ND | ND | Itching, Jaundice, generalized pruritus | enlarged liver with homogenous echo | BD, LT |
| 25. | ND | ND | ND | Itching, pruritus | cholestatic rosettes, fibrosis | LT |
| 26. | ND | ND | Het. | Altered liver enzymes | irregular capsule, coarse echo, multifocal dilation of biliary ducts, cirrhosis | LT |
| 27. | Het. | ND | ND | Itching, Jaundice, fever, tea color urine, GI bleeding, Encephalopathy | Enlarged Liver | LT |
| 28. | Het. | ND | ND | Itching, Jaundice, icteric, sever pruritus, irritability, jaundice, ecchymosis, bleeding tendency | enlarged liver, inhomogeneous echo | LT |
| 29. | Het. | ND | Het. | Jaundice, bleeding tendency, | splenomegaly, hepatomegaly, relative destruction of lobular and vascular architecture, fibrosis | LT |
| 30. | ND | ND | ND | Jaundice, yellowish skin, pruritus | enlarged liver, coarse echo | LT |
| 31. | Het. | ND | ND | prolonged jaundice | cholestatic rosettes, fibrosis | LT |
| 32. | Hom. | ND | ND | jaundice | hepatomegaly, elevated LFT | LT |
| 33. | ND | ND | ND | No data was available | No data was available | - |
| 34. | ND | ND | ND | No data was available | No data was available | - |
| 35. | Het. | ND | ND | sever itching, encephalopathy, ascites, GI bleeding | Cirrhosis, increased echo, enlarged spleen | LT |
It was found that there were 11 and 13 cases of heterozygote and homozygote, respectively, for V444A variation of ABCB11 gene. As mentioned above, this change results in a reduction in the quantity of BSEP protein in liver cells and may be associated with cholestasis in certain conditions, such as pregnancy and the use of ethinylestradiol and levonorgestrel. Among 35 patients involved in this study, 10 cases showed no mutation or variation in the investigated exons of the three genes and other exons should be investigated for their genetic origin. All data are given in Table 2.
Clinical presentation and signs observed in our patients were jaundice, itching, bleeding tendency, fever, tea-color urine, pruritus, ascites, gastrointestinal bleeding, encephalopathy, and itching wounds. Their Para clinical findings on the basis of ultrasonography and histopathological examination indicated enlarged liver, inhomogeneous liver echo, spleen prominent size ascites pleural effusion, cirrhosis, chronic cholecystitis, fibrosis, splenomegaly, hepatomegaly, giant cell formation, and intracalcinular cholestasis (Table 2).
4. Discussion
Molecular genetic testing to identify mutations and variations associated with cholestasis in ATP8B1, ABCB4, and ABCB11 genes is important to confirm PFIC2 diagnosis. Different mutations in these genes have been identified in Asian population (11, 12). The majority of them are different from those identified in other populations. Prevalent mutations that have been reported in Europe were not detected in other regions such as China. Therefore, mutations in these genes may be ethnicity-specific (13)
V444A is a highly prevalent variant of ABCB11 and its allele frequency has been reported in Japanese and Caucasian populations (14). The allele frequency of V444A in the current study was 52.8%. This variation has been previously implicated with higher frequencies in ICP and DIC than normal subjects, suggesting that this variation may become disease relevant in certain conditions (15, 16). However, further larger-scale studies are required to fully uncover the role of V444A variant.
Bile salt export pump (BSEP) is highly conserved during vertebrate evolution, and its expression is inhibited by PFIC type II mutations (17). PFIC type 2 is due to mutations in ABCB11, the gene encoding the BSEP protein. In our study, most of the patients (62.85%) had homozygote mutations in ABCB11 gene. Jaundice, itching, bleeding tendency, fever, tea-color urine, enlarged liver, normal echo, intracellular and intracalcinular cholestasis, cholestasis, pruritus, ascites, GI bleeding, encephalopathy, increased liver echo, cholestasis, giant cell formation fibrosis, and cirrhosis were some of the clinical and Para clinical features of the PFICII in our patients.
ATP8B1 deficiency is a severe autosomal recessive liver disease resulting from mutations in the ATP8B1 gene characterized by a spectrum from intermittent (benign recurrent intrahepatic cholestasis; BRIC) to progressive familial intrahepatic cholestasis (PFIC) (18).
About 20% of our cases had homozygote and heterozygote mutations in their ATP8B1 genes. However, most of them had also mutations in their ABCB11 gene. Jaundice, poor growth, pruritus, encephalopathy, ascites, GI bleeding, enlarged liver, coarse echo, chronic hepatic parenchymal damage, focal steatosis and ballooning degeneration, fibrosis as well as elevated liver enzymes, heterogeneous echo, relative destruction of lobular and vascular architecture, fibrosis, splenomegaly, hepatomegaly, relative destruction of lobular and vascular architecture were clinical and Para clinical findings of the disease in our patients confirmed by the detection of the mutations.
Different molecular methods have been used to investigate mutations in genes associated with cholestasis such as single-strand conformation polymorphisms (SSCP) (19), denaturing high performance liquid chromatography (DHPLC), and DNA sequencing (20). The gold standard is DNA sequencing since it can reveal mutations and variations across three genes with 28 exons for each. However, this method is very expensive. Therefore, the current study tried to investigate common mutations and variations associated with cholestasis in three specific genes and their main exons.
Our study showed that while two common mutations were not identified in our patients, the other common variant, V444A, that previously has been proposed to be associated with cholestasis in certain condition such as pregnancy and the use of ethinylestradiol and levonorgestrel, was identified in a high frequency (37 chromosomes out of 70, 52.8%). The common V444A variant can be investigated in control samples to be concluded for its susceptibility and association with intrahepatic cholestasis in our patients since this variant leads to a reduction in the quantity of BSEP protein in liver cells and can be a good indicator in these patients (15).
In conclusion, the current study investigated common mutations and variations of ATP8B1, ABCB4, ABCB11 genes. V444A was a highly prevalent variation found in ABCB11 in the study. However, it is not fully clear that if they are associated with pediatric cholestatic diseases. More studies should be conducted to investigate this variation, identify the molecular mechanism of ABCB11 product and BSEP and therefore, determine its usefulness in the personalized management of special patients.
There are so many studies that have evaluated the variations in ABCB4, ABCB11 and ATP8B1 genes separately. However, no study investigated the mutations of three genes in each study patient. This is considerable because we found that a large number of our cases (17.14%) had mutations in both ABCB11 and ATP8B1 genes.
One of the limitations of the study was to find patients who voluntarily agreed to participate in this study and donate blood samples. On the other hand, more developed sequencing of related genes, for example whole exon sequencing, was needed to find underlying mutations in cases with no detected mutation using sanger sequencing. In our study, some of the patients had no mutation in interest areas of three mentioned genes, so they should be evaluated by further molecular investigations to find molecular basis of the disease.
Acknowledgements
References
-
1.
Jacquemin E. Progressive Familial Intrahepatic Cholestasis. Clin Liver Dis. 2000;4(4):753-63. https://doi.org/10.1016/s1089-3261(05)70139-2.
-
2.
Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009;4:1. [PubMed ID: 19133130]. https://doi.org/10.1186/1750-1172-4-1.
-
3.
Baussan C, Cresteil D, Gonzales E, Raynaud N, Dumont M, Bernard O, et al. Genetic cholestatic liver diseases: the example of progressive familial intrahepatic cholestasis and related disorders. Acta Gastroenterol Belg. 2004;67(2):179-83. [PubMed ID: 15285575].
-
4.
Thompson R, Strautnieks S. BSEP: function and role in progressive familial intrahepatic cholestasis. Semin Liver Dis. 2001;21(4):545-50. [PubMed ID: 11745042]. https://doi.org/10.1055/s-2001-19038.
-
5.
Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 1998;20(3):233-8. [PubMed ID: 9806540]. https://doi.org/10.1038/3034.
-
6.
Varma S, Revencu N, Stephenne X, Scheers I, Smets F, Beleza-Meireles A, et al. Retargeting of bile salt export pump and favorable outcome in children with progressive familial intrahepatic cholestasis type 2. Hepatology. 2015;62(1):198-206. [PubMed ID: 25847299]. https://doi.org/10.1002/hep.27834.
-
7.
Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis. 2001;21(4):551-62. [PubMed ID: 11745043]. https://doi.org/10.1055/s-2001-19033.
-
8.
Espinosa Fernández MG, Navas López VM, Blasco Alonso J, Sierra Salinas C, Barco Gálvez A. Colestasis intrahepática familiar progresiva tipo 3. Defecto de MDR3. Anales de Pediatría. 2008;69(2):182-4. https://doi.org/10.1157/13124903.
-
9.
Delaunay JL, Durand-Schneider AM, Dossier C, Falguieres T, Gautherot J, Davit-Spraul A, et al. A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3. Hepatology. 2016;63(5):1620-31. [PubMed ID: 26474921]. https://doi.org/10.1002/hep.28300.
-
10.
Jacquemin E, De Vree JM, Cresteil D, Sokal EM, Sturm E, Dumont M, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology. 2001;120(6):1448-58. [PubMed ID: 11313315].
-
11.
Treepongkaruna S, Gaensan A, Pienvichit P, Luksan O, Knisely AS, Sornmayura P, et al. Novel ABCB11 mutations in a Thai infant with progressive familial intrahepatic cholestasis. World J Gastroenterol. 2009;15(34):4339-42. [PubMed ID: 19750581].
-
12.
Goto K, Sugiyama K, Sugiura T, Ando T, Mizutani F, Terabe K, et al. Bile salt export pump gene mutations in two Japanese patients with progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr. 2003;36(5):647-50. [PubMed ID: 12717091].
-
13.
Ananthanarayanan M, Li Y. PFIC2 and ethnicity-specific bile salt export pump (BSEP, ABCB11) mutations: where do we go from here? Liver Int. 2010;30(6):777-9. [PubMed ID: 20214736]. https://doi.org/10.1111/j.1478-3231.2010.02227.x.
-
14.
Lang T, Haberl M, Jung D, Drescher A, Schlagenhaufer R, Keil A, et al. Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11). Drug Metab Dispos. 2006;34(9):1582-99. [PubMed ID: 16763017]. https://doi.org/10.1124/dmd.105.008854.
-
15.
Meier Y, Zodan T, Lang C, Zimmermann R, Kullak-Ublick GA, Meier PJ, et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol. 2008;14(1):38-45. [PubMed ID: 18176959].
-
16.
Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics. 2007;17(1):47-60. [PubMed ID: 17264802]. https://doi.org/10.1097/01.fpc.0000230418.28091.76.
-
17.
Cai SY, Wang L, Ballatori N, Boyer JL. Bile salt export pump is highly conserved during vertebrate evolution and its expression is inhibited by PFIC type II mutations. Am J Physiol Gastrointest Liver Physiol. 2001;281(2):G316-22. [PubMed ID: 11447010].
-
18.
van der Woerd WL, Mulder J, Pagani F, Beuers U, Houwen RH, van de Graaf SF. Analysis of aberrant pre-messenger RNA splicing resulting from mutations in ATP8B1 and efficient in vitro rescue by adapted U1 small nuclear RNA. Hepatology. 2015;61(4):1382-91. [PubMed ID: 25421123]. https://doi.org/10.1002/hep.27620.
-
19.
Strautnieks SS, Byrne JA, Pawlikowska L, Cebecauerova D, Rayner A, Dutton L, et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology. 2008;134(4):1203-14. [PubMed ID: 18395098]. https://doi.org/10.1053/j.gastro.2008.01.038.
-
20.
Liu LY, Wang ZL, Wang XH, Zhu QR, Wang JS. ABCB11 gene mutations in Chinese children with progressive intrahepatic cholestasis and low gamma glutamyltransferase. Liver Int. 2010;30(6):809-15. [PubMed ID: 19845854]. https://doi.org/10.1111/j.1478-3231.2009.02112.x.